Immunocore
Immunocore is a UK-based commercial-stage biotechnology company that develops T cell receptor bispecific immunotherapies using its proprietary ImmTAX platform, commercializing KIMMTRAK (tebentafusp) as the first FDA-approved TCR therapeutic for HLA-A*02:01-positive metastatic uveal melanoma. The company serves rare disease oncology patients globally and has pipeline programs in solid tumors and infectious diseases.
- Company typePublic
- Founded2008
- HeadquartersAbingdon, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immunocore does
Immunocore Holdings plc (NASDAQ: IMCR) is a UK-headquartered, commercial-stage biotechnology company founded in 2008 that pioneered the development of T cell receptor (TCR) bispecific immunotherapies through its proprietary ImmTAX platform. The company's core technology generates soluble TCR molecules engineered to recognize intracellular disease antigens with ultra-high affinity, fused to anti-CD3 immune-effector functions that redirect and activate T cells to destroy target cells. ImmTAX encompasses three modality families: ImmTAC for oncology, ImmTAV for infectious diseases, and gamma delta TCR technology for non-HLA restricted therapies developed with Gadeta. The platform has produced five clinical-stage programs.
The company's sole approved and commercialized product is KIMMTRAK (tebentafusp-tebn), a bispecific TCR targeting gp100 in melanocytes that received FDA approval in January 2022 as the first TCR therapeutic and first bispecific T cell engager approved for a solid tumor. KIMMTRAK is indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma — a rare and aggressive eye cancer with no prior approved therapy — and has demonstrated statistically significant overall survival benefit (hazard ratio 0.51) with five-year survival of 16% versus 8% in the control arm. KIMMTRAK has subsequently received approval from the European Commission, UK MHRA, Australian TGA, Health Canada, and NICE.
Immunocore generates revenue primarily through KIMMTRAK product sales, with FY2025 net sales of $400M (29% YoY growth) and a 96.5% gross margin. Distribution occurs through specialty pharmacy networks and academic medical centers in the US and EU, supplemented by the Medison Pharma partnership covering Canada, Central Eastern Europe, and Israel. The KIMMTRAKConnect patient support program provides nurse case managers, financial assistance, and care coordination. Secondary revenue includes collaboration income from the Genentech/Roche co-development and co-promotion agreement for IMC-C103C (MAGE-A4) and Gates Foundation funding for HIV/HBV programs. The company maintains a cash position of $864.2M and a market valuation of approximately $1.6B.
Immunocore firmographics
Firmographics- Name
- Immunocore
- Legal name
- Immunocore Holdings plc
- Website
- https://immunocore.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Immunocore is a UK-based commercial-stage biotechnology company that develops T cell receptor bispecific immunotherapies using its proprietary ImmTAX platform, commercializing KIMMTRAK (tebentafusp) as the first FDA-approved TCR therapeutic for HLA-A*02:01-positive metastatic uveal melanoma. The company serves rare disease oncology patients globally and has pipeline programs in solid tumors and infectious diseases.
- Ownership category
- akta.pro rank
Immunocore industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Immunocore is headquartered
LocationHeadquarters
- HQ city
- Abingdon
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Immunocore business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- KIMMTRAK Product Sales: Immunocore generates revenue primarily through sales of KIMMTRAK (tebentafusp-tebn), its FDA-approved treatment for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The company commercializes the product directly in the US and EU markets and through distribution partners in other regions. Revenue is generated through product sales to specialty pharmacies and healthcare providers.
- Collaboration Revenue: The company receives collaboration revenue from partnerships such as the co-development and co-promotion agreement with Genentech for IMC-C103C, where Immunocore shares program costs and profits equally. Additionally, the company receives funding from the Bill and Melinda Gates Foundation for HIV and hepatitis B programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | KIMMTRAK is provided as a prescription medication through specialty pharmacy channels with patient support services |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Immunocore product offering
Product offeringCore offering
Immunocore develops and commercializes T cell receptor (TCR) bispecific immunotherapies using its proprietary ImmTAX platform. Its flagship approved product KIMMTRAK (tebentafusp-tebn) is the world's first approved TCR therapeutic, indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The pipeline extends the ImmTAC and ImmTAV platforms to additional solid tumors and infectious diseases including HIV and hepatitis B.
Differentiator
Problem solved
Functional benefit
Brands
- KIMMTRAK (tebentafusp): The company's flagship approved product - a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function for treating metastatic uveal melanoma
- ImmTAX
- ImmTAC
- ImmTAV
Products and services
- KIMMTRAK (tebentafusp-tebn) FDA-approved TCR bispecific biologic for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma; first TCR therapeutic and first bispecific T cell engager approved for a solid tumor; sold to oncology specialty pharmacies and academic medical centers.
- KIMMTRAK (tebentafusp) - EU Marketing Authorization European Commission-approved version of KIMMTRAK for the same metastatic uveal melanoma indication, distributed through regional commercialization partners across EU markets.
- KIMMTRAK (tebentafusp) - UK, Australia, Canada Approval KIMMTRAK approved by UK MHRA, Australian TGA, and Health Canada for treatment of unresectable or metastatic uveal melanoma; sold through regional distribution and commercialization partners.
- IMC-C103C (MAGE-A4 ImmTAC) Investigational ImmTAC bispecific T cell engager targeting MAGE-A4 for treatment of solid tumors including ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and synovial sarcoma; in clinical development under partnership with Genentech.
- IMC-M113V (HIV ImmTAV) Investigational ImmTAV bispecific therapy targeting the HIV Gag antigen presented on HLA-A*02-infected cells, being developed as a potential functional cure for HIV infection.
- IMC-I109V (Hepatitis B ImmTAV) Investigational ImmTAV bispecific therapy targeting a conserved hepatitis B virus envelope antigen, in development as a potential functional cure for chronic hepatitis B infection.
- Brenetafusp (PRAME-targeting ImmTAC) Investigational PRAME-targeting ImmTAC bispecific therapy for heavily pretreated advanced melanoma; clinical-stage candidate with updated Phase 1/2 data reported at ASCO 2026.
- Gamma delta TCR ImmTAC (Gadeta collaboration) Investigational non-HLA-restricted gamma delta TCR ImmTAC bispecific therapy for solid tumors including colorectal cancer, developed under a collaboration with Gadeta.
Quantifiable outcome
- Overall survival hazard ratio of 0.51 (p<0.0001) in metastatic uveal melanoma Phase 3 trial
- +5 more outcomes
Companies that use Immunocore
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles2 records
Immunocore technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Immunocore partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- GadetacoreImmunocore and Gadeta entered into a collaboration agreement to develop the first gamma delta (γδ) TCR ImmTAC for solid tumors, including colorectal cancer. The collaboration combines Gadeta's gamma delta TCR identification expertise with Immunocore's TCR bispecific engineering and commercialization capabilities. Immunocore has an option for an exclusive license to further research, develop and commercialize ImmTAC candidates from the collaboration.
- Medison Pharma Ltd.coreImmunocore entered into an exclusive multi-regional agreement with Medison Pharma to help seek regulatory authorization and commercialize KIMMTRAK (tebentafusp) for the treatment of patients with metastatic uveal melanoma in Canada, twenty markets across Central Eastern Europe and Israel. Medison Pharma provides commercialization services including regulatory support and market access.
- Genentech (Roche Group)coreImmunocore and Genentech have a co-development and co-promotion collaboration for IMC-C103C, an ImmTAC molecule targeting MAGE-A4. Under the agreement, Immunocore shares program costs and profits equally with Genentech. The collaboration includes a Phase 1/2 dose escalation trial evaluating safety and preliminary clinical activity in solid tumors.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Immunocore competitors and assessment
Company assessmentBroad incumbents
- Genmab A/S: Bispecific antibody platform company (DuoBody) with multiple approved and clinical-stage T-cell engagers including epcoritamab (AbbVie partnership). Competes in the same bispecific T-cell redirection modality space as Immunocore's ImmTAC molecules.
- Xencor, Inc. Clinical-stage biotech with XmAb bispecific antibody platform developing T-cell engagers (e.g., vudalimab, plamotamab) and immune-modulating therapeutics. Competes in the bispecific T-cell redirection space with multiple oncology candidates.
- AstraZeneca plc: Global oncology leader with Tagrisso, Imfinzi, Enhertu (with Daiichi Sankyo), and bispecific programs (datopotamab deruxtecan). Competes across solid tumor indications and represents a potential strategic partner or acquirer for pipeline assets.
- Regeneron Pharmaceuticals, Inc. Major bispecific antibody developer with VelociBi platform (linvoseltamab, odronextamab) competing in T-cell engaging therapeutics for solid tumors and hematologic malignancies; broader portfolio including Eylea, Dupixent, and Libtayo oncology.
- Bristol-Myers Squibb Company: Major oncology incumbent with Opdivo (PD-1), Yervoy (CTLA-4), and growing bispecific portfolio. Competes in IO/oncology space and represents both a partner candidate and a competitive threat across Immunocore's solid tumor pipeline.
- Genentech (Roche Holding AG): Existing strategic partner on IMC-C103C (MAGE-A4) and broader oncology leader with multiple bispecifics and IO franchises. Both a commercial collaborator and competitive presence in the solid tumor T-cell engager space.
Direct peers
- MacroGenics, Inc. Clinical-stage bispecific antibody developer (Margenza, enoblituzumab, vobramitamab duocarmazine) focused on solid tumors with DART and TRIDENT platforms enabling T-cell redirecting therapies similar to Immunocore's TCR bispecifics.
- Harpoon Therapeutics (Merck): Developed T-cell engagers (HPN328 targeting DLL3, HPN217) for solid tumors using ProTriTAC and TriTAC platforms; acquired by Merck in 2024. Direct competitor in the T-cell engager space for solid tumors, though no longer independent.
- Adaptimmune Therapeutics plc: Clinical-stage TCR therapy company focused on SPEAR T-cell receptor therapies for solid tumors, including MAGE-A4-targeted Tecelra (afami-cel). Closest direct peer with same TCR-targeting technology and shared MAGE-A4 program space (IMC-C103C).
Emerging players
- Allogene Therapeutics, Inc. Clinical-stage allogeneic CAR-T cell therapy company targeting solid tumors and hematologic malignancies. Represents the cell therapy approach to TCR/CAR-based oncology therapeutics — adjacent modality to Immunocore's soluble TCR bispecifics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Immunocore social profiles
Digital presenceImmunocore financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunocore leadership team
Management profileNumber of profiles
Profiles7 records
Immunocore funding detail
Funding detailFunding overview
Funding rounds8 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunocore M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunocore
What does Immunocore do?
Immunocore develops and commercializes T cell receptor (TCR) bispecific immunotherapies using its proprietary ImmTAX platform. Its flagship approved product KIMMTRAK (tebentafusp-tebn) is the world's first approved TCR therapeutic, indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The pipeline extends the ImmTAC and ImmTAV platforms to additional solid tumors and infectious diseases including HIV and hepatitis B.
Is Immunocore a public or private company?
Immunocore is a public company. It is classified as public and is currently operating.
When was Immunocore founded?
Immunocore was founded in 2008. It employs 251 to 500 people.
Where is Immunocore based?
Immunocore is headquartered in Abingdon, United Kingdom, in the Europe region.
How does Immunocore make money?
Two revenue lines are on record. KIMMTRAK Product Sales are the primary driver. The others are collaboration Revenue.
Who are Immunocore's main competitors?
Broad incumbents on record are Genmab A/S, Xencor, Inc., AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Genentech (Roche Holding AG). Direct peers are MacroGenics, Inc., Harpoon Therapeutics (Merck) and Adaptimmune Therapeutics plc. Allogene Therapeutics, Inc. is listed as an emerging player.
Does Immunocore have an API?
No public API is recorded for Immunocore.
What industry is Immunocore in?
Immunocore's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.